Your browser doesn't support javascript.
loading
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna, Giuseppe Luigi; Addeo, Alfredo; Zygoura, Panagiota; Tsourti, Zoi; Popat, Sanjay; Curioni-Fontecedro, Alessandra; Nadal, Ernest; Shah, Riyaz; Pope, Anthony; Fisher, Patricia; Spicer, James; Roy, Amy; Gilligan, David; Gautschi, Oliver; Janthur, Wolf-Dieter; López-Castro, Rafael; Roschitzki-Voser, Heidi; Dafni, Urania; Peters, Solange; Stahel, Rolf A.
Afiliación
  • Banna GL; Candiolo Cancer Institute, FPO-IRCCCS, Candiolo, Turin, Italy; Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
  • Addeo A; Department of Medical Oncology, Geneva University Hospital (HUG), Genève, Switzerland.
  • Zygoura P; Frontier Science Foundation-Hellas, Athens, Greece.
  • Tsourti Z; Frontier Science Foundation-Hellas, Athens, Greece.
  • Popat S; Lung Unit, Royal Marsden Hospital, and Division of Clinical Studies, Institute of Cancer Research, London, UK.
  • Curioni-Fontecedro A; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Nadal E; Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain.
  • Shah R; Department of Medical Oncology, Kent Oncology Centre, Maidstone, UK.
  • Pope A; Department of Medical Oncology, Clatterbridge Cancer Centre, Liverpool, UK.
  • Fisher P; Department of Medical Oncology, Weston Park Hospital, Sheffield, UK.
  • Spicer J; Department of Medical Oncology, King's College London, Guy's Hospital, London, UK.
  • Roy A; Department of Medical Oncology, University Hospital Plymouth, Plymouth, UK.
  • Gilligan D; Department of Oncology, Addenbrooke's Hospital, Cambridge, UK.
  • Gautschi O; University of Berne and Cantonal Hospital Luzern, Switzerland.
  • Janthur WD; Department of Medical Oncology, Cantonal Hospital Aarau, Switzerland.
  • López-Castro R; Department of Medical Oncology, Hospital Clínico Universitario de Valladolid, Spain.
  • Roschitzki-Voser H; Coordinating Center, European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Dafni U; National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece.
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
  • Stahel RA; Coordinating Center, European Thoracic Oncology Platform (ETOP), Bern, Switzerland. Electronic address: Rolf.Stahel@etop-eu.org.
Lung Cancer ; 169: 77-83, 2022 07.
Article en En | MEDLINE | ID: mdl-35660972
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pleurales / Mesotelioma Maligno / Neoplasias Pulmonares / Mesotelioma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido